AGM FY20 Presentation
Filed with ASX ·
6ix hasn’t read this filing yet.
Arovella Therapeutics Limited on 6ix
Earlier from Arovella Therapeutics
- R & D Tax Incentive refund received
- Investor Presentation November 2020
- Anagrelide Cancer Patent For Australia
- Appendix 4C - quarterly
- TGA Approval Granted For ZolpiMist
Later from Arovella Therapeutics
- AGM FY20 Chairmans address and virtual meeting guide
- Placement Offer to raise $2.76m
- Ordesa Feasibility Study Update
- Prospectus - Placement
- Company Update - Letter to Shareholders
Follow Arovella Therapeutics into a list and get an email when it puts out news.
Follow Arovella Therapeutics